Use of Non-Cryopreserved Peripheral Blood Stem Cells Is Associated with Adequate Engraftment in Patients with Multiple Myeloma Undergoing an Autologous Transplant
The current standard of care for transplant-eligible patients with multiple myeloma is 4 to 6 cycles of induction therapy with 3 drugs, which induces response in 80% to 90% patients, followed by autologous stem cell transplantation [1]. The process of autologous stem cell transplantation starts with stem cell mobilization (using either cytokine or chemotherapy) and stem cell collection followed by administration of high-dose chemotherapy with melphalan and subsequent reinfusion of the collected stem cells.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Uday Kulkarni, Anup J. Devasia, Anu Korula, Fouzia NA, Nisham PN, Yasir J. Samoon, Kavitha M. Lakshmi, Aby Abraham, Alok Srivastava, Vikram Mathews, Biju George Source Type: research